171 related articles for article (PubMed ID: 29372626)
1. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re-analysis of efficacy and safety data from the ML17032 phase III clinical trial.
Chen J; Xiong J; Wang J; Zheng L; Gao Y; Guan Z
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e310-e316. PubMed ID: 29372626
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Kang YK; Kang WK; Shin DB; Chen J; Xiong J; Wang J; Lichinitser M; Guan Z; Khasanov R; Zheng L; Philco-Salas M; Suarez T; Santamaria J; Forster G; McCloud PI
Ann Oncol; 2009 Apr; 20(4):666-73. PubMed ID: 19153121
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
4. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.
Kim ST; Kang JH; Lee J; Park SH; Park JO; Park YS; Lim HY; Hwang IG; Lee SC; Park KW; Lee HR; Kang WK
Eur J Cancer; 2014 Nov; 50(16):2822-30. PubMed ID: 25218337
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Tsuburaya A; Morita S; Kodera Y; Kobayashi M; Shitara K; Yamaguchi K; Yoshikawa T; Yoshida K; Yoshino S; Sakamoto J
BMC Cancer; 2012 Jul; 12():307. PubMed ID: 22824079
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Cho H; Ryu MH; Kim KP; Ryoo BY; Park SR; Kim BS; Lee IS; Kim HS; Yoo MW; Yook JH; Oh ST; Kim BS; Kang YK
Gastric Cancer; 2017 Nov; 20(6):970-977. PubMed ID: 28303362
[TBL] [Abstract][Full Text] [Related]
9. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Shen L; Li J; Xu J; Pan H; Dai G; Qin S; Wang L; Wang J; Yang Z; Shu Y; Xu R; Chen L; Liu Y; Yu S; Bu L; Piao Y
Gastric Cancer; 2015 Jan; 18(1):168-76. PubMed ID: 24557418
[TBL] [Abstract][Full Text] [Related]
11. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer.
Lu Z; Zhang X; Liu W; Liu T; Hu B; Li W; Fan Q; Xu J; Xu N; Bai Y; Pan Y; Xu Q; Bai W; Xia L; Gao Y; Wang W; Shu Y; Shen L
Gastric Cancer; 2018 Sep; 21(5):782-791. PubMed ID: 29488121
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
[TBL] [Abstract][Full Text] [Related]
14. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine for the treatment of advanced gastric cancer.
Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486
[TBL] [Abstract][Full Text] [Related]
17. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Rao S; Starling N; Cunningham D; Sumpter K; Gilligan D; Ruhstaller T; Valladares-Ayerbes M; Wilke H; Archer C; Kurek R; Beadman C; Oates J
Ann Oncol; 2010 Nov; 21(11):2213-2219. PubMed ID: 20497967
[TBL] [Abstract][Full Text] [Related]
18. [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Dong NN; Wang MY; Zhang Q; Liu ZF
Ai Zheng; 2009 Apr; 28(4):412-5. PubMed ID: 19622303
[TBL] [Abstract][Full Text] [Related]
19. Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
Kawakami H; Fujitani K; Matsuyama J; Akamaru Y; Tamura S; Endo S; Kimura Y; Makari Y; Tamura T; Sugimoto N; Sakai D; Tsujinaka T; Goto M; Kurokawa Y; Shimokawa T; Satoh T;
Int J Clin Oncol; 2020 Sep; 25(9):1635-1643. PubMed ID: 32494981
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
Yamaguchi K; Sawaki A; Doi T; Satoh T; Yamada Y; Omuro Y; Nishina T; Boku N; Chin K; Hamamoto Y; Takiuchi H; Komatsu Y; Saji S; Koizumi W; Miyata Y; Sato A; Baba E; Tamura T; Abe T; Ohtsu A
Gastric Cancer; 2013 Apr; 16(2):175-82. PubMed ID: 22782463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
